TACC3 and urinary bladder cancer: We therefore used a selection of highly selective and potent kinase inhibitors targeting relevant genetic aberrations along these pathways in bladder cancer cell lines: FGFRi (AZD4547), PI3Kβ/δi (AZD8186), AKTi (AZD5363) and mTORi (AZD2014); and assayed cell death over 5 days.22, 23, 24, 25 Data relating to RT112, which express constitutively active FGFR3 (FGFR3-TACC3), are shown in Figure 1 and used throughout this study to represent our major findings.26 RT112 cultures showed marked sensitivity to both FGFRi and mTORi, but tolerated AKTi and PI3Kβi (Figure 1a).